Pfēnex Awarded $3.1M for Malaria Work
San Diego-based Pfēnex, a 2009 spinout from Dow Chemical, got a $3.1 million subcontract from SAIC, the Virginia-based government contractor, to help develop a scalable production process for a key Malaria antigen. Pfēnex has developed a technology platform that uses fluorescing bacteria to produce a variety of specialized protein-based products. In a statement today, the companies say Pfēnex is being hired to develop a process for large-scale production of the full-length Circumsporozoite protein from Plasmodium falciparum, the parasite that causes malaria in humans. The subcontract was funded through a $62.4 million prime contract that the National Institutes of Allergy and Infectious Diseases awarded to SAIC.